ScholarIQanswers from OpenAlex & ORCID
Fred Lublin
ResearcherPublications, citations & collaboration network
Fred Lublin is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Fred Lublin have?
ScholarIQindexed works
Fred Lublin has 431 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Fred Lublin have?
ScholarIQcitation count
Fred Lublin has 66,197 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Fred Lublin?
ScholarIQh-index
Fred Lublin has an h-index of 68 in OpenAlex.
What is the i10-index of Fred Lublin?
ScholarIQi10-index
Fred Lublin has an i10-index of 203 in OpenAlex.
What is the ORCID of Fred Lublin?
ScholarIQorcid
The ORCID for Fred Lublin is on the source record.
What is the OpenAlex record for Fred Lublin?
ScholarIQopenalex
The OpenAlex for Fred Lublin is on the source record.
What are the most-cited papers on Fred Lublin?
ScholarIQmost cited works
Defining the clinical course of multiple sclerosis
Fred Lublin, Stephen C. Reingold, Jeffrey A. Cohen, Gary Cutter, Per Soelberg Sørensen, Alan J. Thompson, Jerry S. Wolinsky, Laura J. Balcer, Brenda Banwell, Frederik Barkhof, Bruce F. Bebo, Peter A. Calabresi, Michel Clanet, Giancarlo Comi, Robert J. Fox, Mark S. Freedman, Andrew Goodman, Matilde Inglese, Ludwig Kappos, Bernd C. Kieseier, John A. Lincoln, Catherine Lubetzki, Aaron E. Miller, Xavier Montalbán, Paul O’Connor, John Petkau, Carlo Pozzilli, Richard A. Rudick, Maria Pia Sormani, Olaf Stüve, Emmanuelle Waubant, Chris H. Polman
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Bruce Cree, Jeffrey L. Bennett, Ho Jin Kim, Brian G. Weinshenker, Sean J Pittock, Dean M. Wingerchuk, Kazuo Fujihara, Friedemann Paul, Gary Cutter, Romain Marignier, Ari Green, Orhan Aktaş, Hans‐Peter Hartung, Fred Lublin, Jörn Drappa, Gerard Barron, Soraya Madani, John N. Ratchford, Dewei She, Daniel Cimbora, Eliezer Katz
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Fred Lublin, David H. Miller, Mark S. Freedman, Bruce Cree, Jerry S. Wolinsky, Howard L. Weiner, Catherine Lubetzki, Hans‐Peter Hartung, Xavier Montalbán, Bernard M.J. Uitdehaag, Martin Merschhemke, Bingbing Li, Norman Putzki, Fonda Liu, Dieter A. Häring, Ludwig Kappos
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria
Xavier Montalbán, Christine Lebrun‐Frénay, Jiwon Oh, Georgina Arrambide, Marcello Moccia, Maria Pia Amato, Lilyana Amezcua, Brenda Banwell, Amit Bar-Or, Frederik Barkhof, Helmut Butzkueven, Olga Ciccarelli, Jeremy Chataway, Jeffrey A. Cohen, Giancarlo Comi, Jorge Correale, Florian Deisenhammer, Massimo Filippi, Julie Fiol, Mark S. Freedman, Kazuo Fujihara, Cristina Granziera, Ari Green, Hans-Peter Hartung, Kerstin Hellwig, L Kappos, Dorlan Kimbrough, Joep Killestein, Fred Lublin, Romain Marignier, Ruth Ann Marrie, Aaron Miller, Susana Otero-Romero, Daniel Ontaneda, Sudarshini Ramanathan, Daniel Reich, Maria A. Rocca, Àlex Rovira, Shiv Saidha, Amber Salter, Jaume Sastre‐Garriga, Deanna Saylor, Andrew Solomon, Maria Pia Sormani, Bruno Stankoff, Mar Tintoré, Helen Tremlett, Anneke van der Walt, Shanthi Viswanathan, Heinz Wiendl, Brigitte Wildemann, Bassem Yamout, Paola Zaratin, Peter A. Calabresi, Timothy Coetzee, Alan J. Thompson